| Literature DB >> 22078270 |
Leila J Jackson1, Jed A Pheneger, Tracy J Pheneger, Gregg Davis, A Dale Wright, John E Robinson, Shelley Allen, Mark C Munson, Laura L Carter.
Abstract
PIM kinases are a family of three serine/threonine kinases expressed following T cell activation. Using potent selective small molecule antagonists of PIM-1/3 kinases, we demonstrate a potential role for these enzymes in naïve and effector CD4+ T cell activation. PIM-1/3 inhibition prevented CD4+ T cell proliferation by inducing a G0/G1 cell cycle arrest without affecting cellular survival. In the absence of PIM-1/3 kinase activity, naïve CD4+ T cells failed to fully differentiate into effector cells both in vitro and in vivo. Therapeutic dosing of a PIM-1/3 inhibitor was efficacious in a CD4+ T cell-mediated model of inflammatory bowel disease suggesting that PIM-1 and PIM-3 kinase activity contributes to sustained disease severity. These results demonstrate that PIM-1/3 kinases have an important role in CD4+ T cell responses and inhibition of this activity may provide a therapeutic benefit in T cell-mediated diseases.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22078270 DOI: 10.1016/j.cellimm.2011.10.011
Source DB: PubMed Journal: Cell Immunol ISSN: 0008-8749 Impact factor: 4.868